INSTITUT CURIE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1909-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.curie.fr
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
Not yet recruiting
- Conditions
- Uveal Melanoma
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 250
- Registration Number
- NCT06073548
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Phase 1
Recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Combination Product: Atezolizumab + RP1
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 51
- Registration Number
- NCT06067061
- Locations
- 🇫🇷
Institut Curie, Paris, France
Study for the Reliability and Validity of the EORTC PATSAT-C33 and the EORTC OUT-PATSAT7 Questionnaires
Active, not recruiting
- Conditions
- Cancer
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 690
- Registration Number
- NCT05989191
- Locations
- 🇫🇷
Institut Curie, Paris, France
🇫🇷Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
Phase 2
Recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 66
- Registration Number
- NCT05955170
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, Clermont Ferrand, France
🇫🇷CHU Amiens Picardie-Site Sud, Amiens, France
🇫🇷Institut Sainte Catherine, Avignon, France
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Behavioral: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 1
- Registration Number
- NCT05932667
- Locations
- 🇫🇷
Institut Du Cancer Montpellier, Montpellier, France
🇫🇷Institut Curie, Saint-Cloud, France
🇫🇷Centre Eugene Marquis, Rennes, France
Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology
Not Applicable
Recruiting
- Conditions
- ChildrenOncologyMedical DevicePrimary Prevention
- Interventions
- Device: Physiological serumDevice: TaurolockTM
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 148
- Registration Number
- NCT05781295
- Locations
- 🇫🇷
Saint Louis, Paris, France
🇫🇷Institut Curie, Paris, France
🇫🇷Armand Trousseau, Paris, France
Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Device: Activity tracker
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 200
- Registration Number
- NCT05634395
- Locations
- 🇫🇷
Institut Curie, Saint-Cloud, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut GODINOT, Reims, France
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)
Not Applicable
Recruiting
- Conditions
- Cancer
- Interventions
- Other: single arm for all patients
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 50
- Registration Number
- NCT05558644
- Locations
- 🇫🇷
Institut Curie Paris, Paris, France
🇫🇷Institut Mutualiste Montsouris, Paris, France
🇫🇷Hôpital FOCH, Suresnes, France
Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2
Recruiting
- Conditions
- Quality of LifeCancerIMMUNE CHECKPOINT INHIBITOR
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 43
- Registration Number
- NCT05554432
- Locations
- 🇫🇷
Institut Curie, Paris, France
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
Not Applicable
Recruiting
- Conditions
- Carcinoma, Pancreatic DuctalPrognosis
- Interventions
- Other: Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDACOther: Biomarkers of tumor signatures (translational studies)
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 62
- Registration Number
- NCT05475366
- Locations
- 🇫🇷
CHU Robert Debré, Reims, France
🇫🇷Hôpital Beaujon, Clichy, France
🇫🇷Hôpital HENRI MONDOR, Créteil, France
© Copyright 2025. All Rights Reserved by MedPath